ClinicalTrials.gg
Active, not recruitingNCT06489028Updated Oct 1, 2025

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)

A Phase 3 interventional study of allo-APZ2-CVU and Placebo in Venous Leg Ulcer, sponsored by RHEACELL GmbH & Co. KG. Active, not recruiting at 15 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by RHEACELL GmbH & Co. KG · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 155 studies in Varicose Ulcer with a site in United States — 33 open to participants now, 43 under way, 4 of them phase 3. Varicose Ulcer · United States.

Planned enrollment
15th of 132
250 · median 53
Started
2024
with 12 others
Phase 3
10 of 155
3 open now
Primary completion
2027-04
later than 30 of 42 live
Registered
126th of 155
by date

Among the 155 studies in Varicose Ulcer with a site in United States, this one is the 15th largest by planned enrollment of the 132 interventional ones that give a count, is one of 13 that started in 2024, is one of 10 in phase 3, reaches primary completion later than 30 of the 42 other live ones, and was the 126th registered.

Varicose Ulcer

371 studies on the registry are indexed under Varicose Ulcer; 75 are open to participants now.

Browse Varicose Ulcer studies →

Open to participants now

33 of the 155 studies in Varicose Ulcer with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Varicose Ulcer studies recruiting now, 40 (80%) set no upper age limit and 5 (10%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Varicose Ulcer with a site in United States, or all of them as a file.
02

Study summary

The aim of this clinical trial is to investigate the efficacy and safety of allo-APZ2-CVU, administered topically on therapy-resistant non-healing CVUs compared to placebo.

Read the detailed description

This is a pivotal, randomized, placebo-controlled, double-blind, multicenter, international phase III clinical trial to investigate the efficacy and safety of the IMP allo-APZ2-CVU on wound healing in patients with therapy-resistant non-healing CVU.

The allogeneic IMP allo-APZ2-CVU contains skin-derived ABCB5-positive dermal mesenchymal stromal cells isolated from skin tissue of healthy donors and stored in a donor cell bank.

Patients will be randomized to be treated with allo-APZ2-CVU or placebo. The patients will undergo treatment with the IMP on Day 0 (V3) and will be followed up for efficacy for 18 weeks (V4 until V14). Three safety follow-up visits will be performed at Month 6 (V15), Month 10 (V16) and Month 16 (V17).

The wound healing process will be documented by standardized photography.

The wound size measurement will start at the first Screening Visit (V1) and will be measured at each following on-site visit.

Pain will be assessed using a numerical rating scale and quality of life will be investigated with standardized and validated questionnaires.

03

Conditions studied

  • Venous Leg Ulcer

Keywords

  • Chronic Venous Ulcer
  • ABCB5
  • Allogeneic
  • Dermal mesenchymal stromal cells
  • varicose ulcer
  • skin ulcer
  • advanced therapy medicinal product
  • somatic cell therapy
  • phase III
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients at least 18 years old;
  2. Chronic venous leg ulcer at lower leg and/or ankle region that has not been present longer than 15 years, diagnosed by Doppler or Duplex sonography, ankle brachial index, physical examination and dermatological review;
  3. Wound size at V1 and V2 between 1 and 25 cm˄2 as measured by standardized photography;
  4. If patients have 2 or more ulcers at the same extremity, the target ulcer has to be separated from the other ulcers with a bridge of epithelialized skin at least 1 cm wide;
  5. between 15 and 50 kg/m²;
  6. Patients able to understand the nature of the study and able to provide written prior to any clinical trial procedures;
  7. Women of must have a negative urine pregnancy test at Visit 1;
  8. During the course of the clinical trial women of childbearing potential and their male partners must be willing to use highly effective methods as defined in the EMA CTCG "Recommendations related to contraception and pregnancy testing in clinical trials" Version 1.2.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of the ulcer extending to the underlying muscle, tendon, or bone;
  2. Uncontrolled Diabetes mellitus i.e. (HbA1c) >9.0% (75 mmol/mol) (measured by blood test);
  3. Peripheral Artery Disease including claudication with need of treatment or intervention;
  4. Acute deep vein thrombosis diagnosed within 30 days before V1, or untreated deep vein thrombosis;
  5. Wounds showing size reduction of more than 40% at Visit 2 compared to Visit 1;
  6. Patients with known and/or clinical to the compression systems used in the clinical trial, or inability/unwillingness to tolerate leg ulcer compression systems;
  7. Acute wound infection of ulcer requiring treatment as judged clinically;
  8. Current use of medications that are known to influence wound healing i.e. systemic immunosuppressives, cytotoxic medicinal products, systemic (above Cushingthreshold level) at investigator´s discretion;
  9. Patients who, in the opinion of the investigator, for any reason are unable or unwilling to complete the trial per protocol (e.g. alcohol or substance abuse, not mobile, short ) or there is an evidence of any other medical condition (such as psychiatric illness, physical examination, or laboratory findings) that may interfere with the planned treatment, affect the patient's compliance, or place the patient at high risk of complications related to the treatment;
  10. Any within the past 5 years, excluding successfully treated carcinoma in situ, basal cell carcinoma or squamous cell carcinoma of the skin without evidence of ;
  11. Pregnant or lactating women;
  12. Known hypersensitivities to the active substance or to any of the in the IP or the placebo;
  13. Surgical procedure affecting the CVU, such as bypass or mesh graft performed within two months prior to Visit 1;
  14. Current or previous (within 30 days of enrollment) treatment with another IP, or participation in another clinical trial, including follow-up phase;
  15. Previous participation in this clinical trial (except for screening failures due to an inclusion or exclusion criterion);
  16. Employees of the sponsor, or employees or relatives of the investigator(s).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Verum

    Drug: allo-APZ2-CVU

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Drugallo-APZ2-CVU

    Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Complete wound closure

    Complete wound closure already persisting for at least two weeks

    Time frame: 18 weeks

Secondary outcomes

  1. Complete wound closures at each post-baseline follow-up visit

    Complete wound closures at each post-baseline follow-up visit

    Time frame: at each post-baseline follow-up visit (starting the day after intervention until month 16)

07

Study locations

15 sites
  • RHEACELL Clinical Trial Site
    Hialeah, Florida 33012, United States
  • RHEACELL Clinical Trial Site
    Miami, Florida 33136, United States
  • RHEACELL Clinical Trial Site
    Boston, Massachusetts 02114, United States
  • RHEACELL Clinical Trial Site
    Minneapolis, Minnesota 55455, United States
  • RHEACELL Clinical Trial Site
    Multiple Locations, Austria
  • RHEACELL Clinical Trial Site
    Multiple Locations, Czechia
  • RHEACELL Clinical Trial Site
    Multiple Locations, France
  • RHEACELL Clinical Trial Site
    Several Locations, Germany
  • RHEACELL Clinical Trial Site
    Multiple Locations, Hungary
  • RHEACELL Clinical Trial Site
    Multiple Locations, Italy
  • RHEACELL Clinical Trial Site
    Multiple Locations, Netherlands
  • RHEACELL Clinical Trial Site
    Multiple Locations, Poland
  • RHEACELL Clinical Trial Site
    Multiple Locations, Slovakia
  • RHEACELL Clinical Trial Site
    Multiple Locations, Sweden
  • RHEACELL Clinical Trial Site
    Multiple Locations, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Apr 2027, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2024
First posted
Jul 5, 2024
StartActual
Dec 26, 2024
Primary completionEst.
Apr 2027
CompletionEst.
Sep 2027
Last update
Oct 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06489028
Lead sponsor
RHEACELL GmbH & Co. KG
Collaborators
FGK Clinical Research GmbH
Responsible party
Sponsor
First posted
Jul 5, 2024
Start date
Dec 26, 2024
Primary completion
Apr 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 1, 2025

Study contacts

Anna Moessmer
study director · RHEACELL GmbH & Co. KG

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion